APO Research
Talk to an analyst

APO RESEARCH · REPORT

CD11b Antibody

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global CD11b Antibody Market Outlook and Growth Opportunities 2026

19 December 2025205 pages

Choose your research edition.

Industry ResearchCD11b Antibody Industry Research Report 2026131 pages · $2,950 USDIndustry Growth & TrendsGlobal CD11b Antibody Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal CD11b Antibody Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal CD11b Antibody Market Outlook and Growth Opportunities 2026205 pages · $4,250 USDMarket Analysis & ForecastGlobal CD11b Antibody Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global CD11b Antibody market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for CD11b Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for CD11b Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for CD11b Antibody is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the CD11b Antibody market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the CD11b Antibody market include Merck, Boster Biological Technology, United States Biological, Synaptic, Santa Cruz Biotechnology, Proteintech, Miltenyi Biotec, Hytest and GeneTex, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global CD11b Antibody market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of CD11b Antibody and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents CD11b Antibody revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global CD11b Antibody market.

CD11b Antibody Segment by Company

Merck

Boster Biological Technology

United States Biological

Synaptic

Santa Cruz Biotechnology

Proteintech

Miltenyi Biotec

Hytest

GeneTex

FineTest

EXBIO

Everest Biotech

Bio-Rad

BioLegend

Bio X Cell

Beckman Coulter

Atlas Antibodies

CD11b Antibody Segment by Type

Polyclonal

Monoclonal

CD11b Antibody Segment by Application

Western Blot

Flow Cytometry

Enzyme Linked Immunosorbent Assay

Immunoprecipitation

Immunofluorescence

Others

CD11b Antibody Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global CD11b Antibody status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the CD11b Antibody key companies, revenue, market share, and recent developments.

3. To split the CD11b Antibody breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions CD11b Antibody market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify CD11b Antibody significant trends, drivers, influence factors in global and regions.

6. To analyze CD11b Antibody competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global CD11b Antibody market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of CD11b Antibody and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of CD11b Antibody.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global CD11b Antibody industry.

Chapter 3: Detailed analysis of CD11b Antibody company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of CD11b Antibody in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of CD11b Antibody in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. CD11b Antibody Industry Trends Table 2. CD11b Antibody Industry Drivers Table 3. CD11b Antibody Industry Opportunities and Challenges Table 4. CD11b Antibody Industry Restraints Table 5. Global CD11b Antibody Revenue by Company (US$ Million) & (2021-2026) Table 6. Global CD11b Antibody Revenue Share by Company (2021-2026) Table 7. Global CD11b Antibody Company Ranking, (2024-2026) & (US$ Million) Table 8. Global CD11b Antibody Key Company Manufacturing Base & Headquarters Table 9. Global CD11b Antibody Company, Product Type & Application Table 10. Global CD11b Antibody Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global CD11b Antibody by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Polyclonal Table 15. Significant Companies of Monoclonal Table 16. Global CD11b Antibody Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global CD11b Antibody Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global CD11b Antibody Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global CD11b Antibody Sales Value Share by Type (2021-2026) Table 20. Global CD11b Antibody Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Western Blot Table 22. Significant Companies of Flow Cytometry Table 23. Significant Companies of Enzyme Linked Immunosorbent Assay Table 24. Significant Companies of Immunoprecipitation Table 25. Significant Companies of Immunofluorescence Table 26. Significant Companies of Others Table 27. Global CD11b Antibody Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 28. Global CD11b Antibody Sales Value by Application (2021-2026) & (US$ Million) Table 29. Global CD11b Antibody Sales Value by Application (2027-2032) & (US$ Million) Table 30. Global CD11b Antibody Sales Value Share by Application (2021-2026) Table 31. Global CD11b Antibody Sales Value Share by Application (2027-2032) Table 32. Global CD11b Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 33. Global CD11b Antibody Sales Value by Region (2021-2026) & (US$ Million) Table 34. Global CD11b Antibody Sales Value Share by Region (2021-2026) Table 35. Global CD11b Antibody Sales Value by Region (2027-2032) & (US$ Million) Table 36. Global CD11b Antibody Sales Value Share by Region (2027-2032) Table 37. Global CD11b Antibody Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global CD11b Antibody Sales Value by Country (2021-2026) & (US$ Million) Table 39. Global CD11b Antibody Sales Value Market Share by Country (2021-2026) Table 40. Global CD11b Antibody Sales Value by Country (2027-2032) & (US$ Million) Table 41. Global CD11b Antibody Sales Value Market Share by Country (2027-2032) Table 42. Merck Company Information Table 43. Merck Business Overview Table 44. Merck CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 45. Merck CD11b Antibody Product Portfolio Table 46. Merck Recent Development Table 47. Boster Biological Technology Company Information Table 48. Boster Biological Technology Business Overview Table 49. Boster Biological Technology CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 50. Boster Biological Technology CD11b Antibody Product Portfolio Table 51. Boster Biological Technology Recent Development Table 52. United States Biological Company Information Table 53. United States Biological Business Overview Table 54. United States Biological CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 55. United States Biological CD11b Antibody Product Portfolio Table 56. United States Biological Recent Development Table 57. Synaptic Company Information Table 58. Synaptic Business Overview Table 59. Synaptic CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 60. Synaptic CD11b Antibody Product Portfolio Table 61. Synaptic Recent Development Table 62. Santa Cruz Biotechnology Company Information Table 63. Santa Cruz Biotechnology Business Overview Table 64. Santa Cruz Biotechnology CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 65. Santa Cruz Biotechnology CD11b Antibody Product Portfolio Table 66. Santa Cruz Biotechnology Recent Development Table 67. Proteintech Company Information Table 68. Proteintech Business Overview Table 69. Proteintech CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 70. Proteintech CD11b Antibody Product Portfolio Table 71. Proteintech Recent Development Table 72. Miltenyi Biotec Company Information Table 73. Miltenyi Biotec Business Overview Table 74. Miltenyi Biotec CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 75. Miltenyi Biotec CD11b Antibody Product Portfolio Table 76. Miltenyi Biotec Recent Development Table 77. Hytest Company Information Table 78. Hytest Business Overview Table 79. Hytest CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 80. Hytest CD11b Antibody Product Portfolio Table 81. Hytest Recent Development Table 82. GeneTex Company Information Table 83. GeneTex Business Overview Table 84. GeneTex CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 85. GeneTex CD11b Antibody Product Portfolio Table 86. GeneTex Recent Development Table 87. FineTest Company Information Table 88. FineTest Business Overview Table 89. FineTest CD11b Antibody Revenue (US$ Million) and Gross Margin (2021-2026) Table 90. FineTest CD11b Antibody Product Portfolio Table 91. FineTest Recent Development Table 92. EXBIO Company Information Table 93. EXBIO Business Overview Table 94. EXBIO CD11b Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 95. EXBIO CD11b Antibody Product Portfolio Table 96. EXBIO Recent Development Table 97. Everest Biotech Company Information Table 98. Everest Biotech Business Overview Table 99. Everest Biotech CD11b Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 100. Everest Biotech CD11b Antibody Product Portfolio Table 101. Everest Biotech Recent Development Table 102. Bio-Rad Company Information Table 103. Bio-Rad Business Overview Table 104. Bio-Rad CD11b Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 105. Bio-Rad CD11b Antibody Product Portfolio Table 106. Bio-Rad Recent Development Table 107. BioLegend Company Information Table 108. BioLegend Business Overview Table 109. BioLegend CD11b Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 110. BioLegend CD11b Antibody Product Portfolio Table 111. BioLegend Recent Development Table 112. Bio X Cell Company Information Table 113. Bio X Cell Business Overview Table 114. Bio X Cell CD11b Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 115. Bio X Cell CD11b Antibody Product Portfolio Table 116. Bio X Cell Recent Development Table 117. Beckman Coulter Company Information Table 118. Beckman Coulter Business Overview Table 119. Beckman Coulter CD11b Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 120. Beckman Coulter CD11b Antibody Product Portfolio Table 121. Beckman Coulter Recent Development Table 122. Atlas Antibodies Company Information Table 123. Atlas Antibodies Business Overview Table 124. Atlas Antibodies CD11b Antibody Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 125. Atlas Antibodies CD11b Antibody Product Portfolio Table 126. Atlas Antibodies Recent Development Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. CD11b Antibody Product Image Figure 2. Global CD11b Antibody Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global CD11b Antibody Market Size (2021-2032) & (US$ Million) Figure 4. Global CD11b Antibody Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Polyclonal Image Figure 8. Monoclonal Image Figure 9. Global CD11b Antibody Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global CD11b Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global CD11b Antibody Sales Value Share by Type (2021-2032) Figure 12. Western Blot Image Figure 13. Flow Cytometry Image Figure 14. Enzyme Linked Immunosorbent Assay Image Figure 15. Immunoprecipitation Image Figure 16. Immunofluorescence Image Figure 17. Others Image Figure 18. Global CD11b Antibody Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global CD11b Antibody Sales Value Share 2021 VS 2025 VS 2032 Figure 20. Global CD11b Antibody Sales Value Share by Application (2021-2032) Figure 21. Global CD11b Antibody Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 22. Global CD11b Antibody Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 23. North America CD11b Antibody Sales Value (2021-2032) & (US$ Million) Figure 24. North America CD11b Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Europe CD11b Antibody Sales Value (2021-2032) & (US$ Million) Figure 26. Europe CD11b Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Asia-Pacific CD11b Antibody Sales Value (2021-2032) & (US$ Million) Figure 28. Asia-Pacific CD11b Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 29. South America CD11b Antibody Sales Value (2021-2032) & (US$ Million) Figure 30. South America CD11b Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Middle East & Africa CD11b Antibody Sales Value (2021-2032) & (US$ Million) Figure 32. Middle East & Africa CD11b Antibody Sales Value Share by Country (%), 2025 VS 2032 Figure 33. USA CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. USA CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. USA CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Canada CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Canada CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Canada CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Mexico CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Mexico CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Mexico CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Germany CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Germany CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Germany CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. France CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. France CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. France CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. U.K. CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. U.K. CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. U.K. CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Italy CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Italy CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Italy CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Spain CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Spain CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Spain CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Russia CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Russia CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Russia CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Netherlands CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Netherlands CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Netherlands CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Nordic Countries CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Nordic Countries CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Nordic Countries CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. China CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. China CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. China CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Japan CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Japan CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Japan CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. South Korea CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. South Korea CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. South Korea CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. India CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. India CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. India CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Australia CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Australia CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Australia CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Southeast Asia CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Southeast Asia CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Southeast Asia CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Brazil CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Brazil CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Brazil CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Argentina CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Argentina CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Argentina CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Chile CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Chile CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Chile CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Colombia CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Colombia CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Colombia CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Peru CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Peru CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Peru CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Saudi Arabia CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Saudi Arabia CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Saudi Arabia CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Israel CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Israel CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Israel CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. UAE CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. UAE CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. UAE CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Turkey CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Turkey CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Turkey CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Iran CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Iran CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Iran CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Egypt CD11b Antibody Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Egypt CD11b Antibody Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Egypt CD11b Antibody Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Years Considered Figure 118. Research Process Figure 119. Key Executives Interviewed

Scope & coverage.

Types
  • Polyclonal
  • Monoclonal
Applications
  • Western Blot
  • Flow Cytometry
  • Enzyme Linked Immunosorbent Assay
  • Immunoprecipitation
  • Immunofluorescence
  • Others
Companies covered
  • Merck
  • Boster Biological Technology
  • United States Biological
  • Synaptic
  • Santa Cruz Biotechnology
  • Proteintech
  • Miltenyi Biotec
  • Hytest
  • GeneTex
  • FineTest
  • EXBIO
  • Everest Biotech
  • Bio-Rad
  • BioLegend
  • Bio X Cell
  • Beckman Coulter
  • Atlas Antibodies

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global CD11b Antibody Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global CD11b Antibody Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 CD11b Antibody Market Dynamics
  1. 2.1 CD11b Antibody Industry Trends
  2. 2.2 CD11b Antibody Industry Drivers
  3. 2.3 CD11b Antibody Industry Opportunities and Challenges
  4. 2.4 CD11b Antibody Industry Restraints
3 CD11b Antibody Market by Company
  1. 3.1 Global CD11b Antibody Company Revenue Ranking in 2025
  2. 3.2 Global CD11b Antibody Revenue by Company (2021-2026)
  3. 3.3 Global CD11b Antibody Company Ranking (2024-2026)
  4. 3.4 Global CD11b Antibody Company Manufacturing Base and Headquarters
  5. 3.5 Global CD11b Antibody Company Product Type and Application
  6. 3.6 Global CD11b Antibody Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global CD11b Antibody Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 CD11b Antibody Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 CD11b Antibody Market by Type
  1. 4.1 CD11b Antibody Type Introduction
  2. 4.1.1 Polyclonal
  3. 4.1.2 Monoclonal
  4. 4.2 Global CD11b Antibody Sales Value by Type
  5. 4.2.1 Global CD11b Antibody Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global CD11b Antibody Sales Value by Type (2021-2032)
  7. 4.2.3 Global CD11b Antibody Sales Value Share by Type (2021-2032)
5 CD11b Antibody Market by Application
  1. 5.1 CD11b Antibody Application Introduction
  2. 5.1.1 Western Blot
  3. 5.1.2 Flow Cytometry
  4. 5.1.3 Enzyme Linked Immunosorbent Assay
  5. 5.1.4 Immunoprecipitation
  6. 5.1.5 Immunofluorescence
  7. 5.1.6 Others
  8. 5.2 Global CD11b Antibody Sales Value by Application
  9. 5.2.1 Global CD11b Antibody Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.2.2 Global CD11b Antibody Sales Value by Application (2021-2032)
  11. 5.2.3 Global CD11b Antibody Sales Value Share by Application (2021-2032)
6 CD11b Antibody Regional Value Analysis
  1. 6.1 Global CD11b Antibody Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global CD11b Antibody Sales Value by Region (2021-2032)
  3. 6.2.1 Global CD11b Antibody Sales Value by Region: 2021-2026
  4. 6.2.2 Global CD11b Antibody Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America CD11b Antibody Sales Value (2021-2032)
  7. 6.3.2 North America CD11b Antibody Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe CD11b Antibody Sales Value (2021-2032)
  10. 6.4.2 Europe CD11b Antibody Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific CD11b Antibody Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific CD11b Antibody Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America CD11b Antibody Sales Value (2021-2032)
  16. 6.6.2 South America CD11b Antibody Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa CD11b Antibody Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa CD11b Antibody Sales Value Share by Country, 2025 VS 2032
7 CD11b Antibody Country-level Value Analysis
  1. 7.1 Global CD11b Antibody Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global CD11b Antibody Sales Value by Country (2021-2032)
  3. 7.2.1 Global CD11b Antibody Sales Value by Country (2021-2026)
  4. 7.2.2 Global CD11b Antibody Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA CD11b Antibody Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada CD11b Antibody Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico CD11b Antibody Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany CD11b Antibody Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France CD11b Antibody Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. CD11b Antibody Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy CD11b Antibody Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain CD11b Antibody Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia CD11b Antibody Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands CD11b Antibody Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries CD11b Antibody Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China CD11b Antibody Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan CD11b Antibody Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea CD11b Antibody Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India CD11b Antibody Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia CD11b Antibody Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia CD11b Antibody Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil CD11b Antibody Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina CD11b Antibody Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile CD11b Antibody Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia CD11b Antibody Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru CD11b Antibody Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia CD11b Antibody Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel CD11b Antibody Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE CD11b Antibody Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey CD11b Antibody Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran CD11b Antibody Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran CD11b Antibody Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt CD11b Antibody Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt CD11b Antibody Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt CD11b Antibody Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Merck
  2. 8.1.1 Merck Company Information
  3. 8.1.2 Merck Business Overview
  4. 8.1.3 Merck CD11b Antibody Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Merck CD11b Antibody Product Portfolio
  6. 8.1.5 Merck Recent Developments
  7. 8.2 Boster Biological Technology
  8. 8.2.1 Boster Biological Technology Company Information
  9. 8.2.2 Boster Biological Technology Business Overview
  10. 8.2.3 Boster Biological Technology CD11b Antibody Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Boster Biological Technology CD11b Antibody Product Portfolio
  12. 8.2.5 Boster Biological Technology Recent Developments
  13. 8.3 United States Biological
  14. 8.3.1 United States Biological Company Information
  15. 8.3.2 United States Biological Business Overview
  16. 8.3.3 United States Biological CD11b Antibody Revenue and Gross Margin (2021-2026)
  17. 8.3.4 United States Biological CD11b Antibody Product Portfolio
  18. 8.3.5 United States Biological Recent Developments
  19. 8.4 Synaptic
  20. 8.4.1 Synaptic Company Information
  21. 8.4.2 Synaptic Business Overview
  22. 8.4.3 Synaptic CD11b Antibody Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Synaptic CD11b Antibody Product Portfolio
  24. 8.4.5 Synaptic Recent Developments
  25. 8.5 Santa Cruz Biotechnology
  26. 8.5.1 Santa Cruz Biotechnology Company Information
  27. 8.5.2 Santa Cruz Biotechnology Business Overview
  28. 8.5.3 Santa Cruz Biotechnology CD11b Antibody Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Santa Cruz Biotechnology CD11b Antibody Product Portfolio
  30. 8.5.5 Santa Cruz Biotechnology Recent Developments
  31. 8.6 Proteintech
  32. 8.6.1 Proteintech Company Information
  33. 8.6.2 Proteintech Business Overview
  34. 8.6.3 Proteintech CD11b Antibody Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Proteintech CD11b Antibody Product Portfolio
  36. 8.6.5 Proteintech Recent Developments
  37. 8.7 Miltenyi Biotec
  38. 8.7.1 Miltenyi Biotec Company Information
  39. 8.7.2 Miltenyi Biotec Business Overview
  40. 8.7.3 Miltenyi Biotec CD11b Antibody Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Miltenyi Biotec CD11b Antibody Product Portfolio
  42. 8.7.5 Miltenyi Biotec Recent Developments
  43. 8.8 Hytest
  44. 8.8.1 Hytest Company Information
  45. 8.8.2 Hytest Business Overview
  46. 8.8.3 Hytest CD11b Antibody Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Hytest CD11b Antibody Product Portfolio
  48. 8.8.5 Hytest Recent Developments
  49. 8.9 GeneTex
  50. 8.9.1 GeneTex Company Information
  51. 8.9.2 GeneTex Business Overview
  52. 8.9.3 GeneTex CD11b Antibody Revenue and Gross Margin (2021-2026)
  53. 8.9.4 GeneTex CD11b Antibody Product Portfolio
  54. 8.9.5 GeneTex Recent Developments
  55. 8.10 FineTest
  56. 8.10.1 FineTest Company Information
  57. 8.10.2 FineTest Business Overview
  58. 8.10.3 FineTest CD11b Antibody Revenue and Gross Margin (2021-2026)
  59. 8.10.4 FineTest CD11b Antibody Product Portfolio
  60. 8.10.5 FineTest Recent Developments
  61. 8.11 EXBIO
  62. 8.11.1 EXBIO Company Information
  63. 8.11.2 EXBIO Business Overview
  64. 8.11.3 EXBIO CD11b Antibody Revenue and Gross Margin (2021-2026)
  65. 8.11.4 EXBIO CD11b Antibody Product Portfolio
  66. 8.11.5 EXBIO Recent Developments
  67. 8.12 Everest Biotech
  68. 8.12.1 Everest Biotech Company Information
  69. 8.12.2 Everest Biotech Business Overview
  70. 8.12.3 Everest Biotech CD11b Antibody Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Everest Biotech CD11b Antibody Product Portfolio
  72. 8.12.5 Everest Biotech Recent Developments
  73. 8.13 Bio-Rad
  74. 8.13.1 Bio-Rad Company Information
  75. 8.13.2 Bio-Rad Business Overview
  76. 8.13.3 Bio-Rad CD11b Antibody Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bio-Rad CD11b Antibody Product Portfolio
  78. 8.13.5 Bio-Rad Recent Developments
  79. 8.14 BioLegend
  80. 8.14.1 BioLegend Company Information
  81. 8.14.2 BioLegend Business Overview
  82. 8.14.3 BioLegend CD11b Antibody Revenue and Gross Margin (2021-2026)
  83. 8.14.4 BioLegend CD11b Antibody Product Portfolio
  84. 8.14.5 BioLegend Recent Developments
  85. 8.15 Bio X Cell
  86. 8.15.1 Bio X Cell Company Information
  87. 8.15.2 Bio X Cell Business Overview
  88. 8.15.3 Bio X Cell CD11b Antibody Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Bio X Cell CD11b Antibody Product Portfolio
  90. 8.15.5 Bio X Cell Recent Developments
  91. 8.16 Beckman Coulter
  92. 8.16.1 Beckman Coulter Company Information
  93. 8.16.2 Beckman Coulter Business Overview
  94. 8.16.3 Beckman Coulter CD11b Antibody Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Beckman Coulter CD11b Antibody Product Portfolio
  96. 8.16.5 Beckman Coulter Recent Developments
  97. 8.17 Atlas Antibodies
  98. 8.17.1 Atlas Antibodies Company Information
  99. 8.17.2 Atlas Antibodies Business Overview
  100. 8.17.3 Atlas Antibodies CD11b Antibody Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Atlas Antibodies CD11b Antibody Product Portfolio
  102. 8.17.5 Atlas Antibodies Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst